Trailing-twelve-month (TTM) revenue is $1.65 Billion with a year-over-year growth of +1.60%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $402,062,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $434,925,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $391,918,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $418,761,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-29 |
| TTM revenue | $1,647,666,000 |
Current P/S: $1,033,596,602 market capitalization ÷ $1,647,666,000 TTM revenue = 0.63x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:20:50.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $418.76M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:22:52.438Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Codman Specialty Surgical | $996M | $895M | $1.0B | $1.0B | $1.1B | $1.2B |
| Orthopedics and Tissue Technologies | $521M | $477M | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Asia Pacific | $157M | $157M | $182M | $176M | $177M | $189M |
| Europe | $197M | $173M | $191M | $171M |
$1.65B
$1.65 Billion
+1.60%
vs. $1.62B a year ago (TTM)
+1.77%
5 Year compound annual growth rate
1 Year
+1.60%
3 Year
+2.16%
5 Year
+1.77%
10 Year
+5.62%
15 Year
+5.34%
20 Year
+8.55%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.64B | +$24.72M | +1.53% |
| 2024 | $1.61B | +$68.95M | +4.47% |
| 2023 | $1.54B | ($16.09M) | (1.03%) |
| 2022 | $1.56B | +$15.22M | +0.99% |
| 2021 | $1.54B | +$170.58M | +12.43% |
| 2020 |
TTM Growth
+1.60%
3-Year CAGR
+2.16%
5-Year CAGR
+1.77%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T16:22:52.438Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| Tissue Technologies | N/A | N/A | $517M | $538M | $467M | $435M |
|---|
| $163M |
| Rest Of The World | N/A | N/A | N/A | N/A | $83M | $79M |
|---|
| Rest Of World | $85M | $70M | $80M | $83M | N/A | N/A |
|---|
| UNITED STATES | $1.1B | $972M | $1.1B | $1.1B | $1.2B | $1.2B |
|---|
| $1.37B |
| ($145.69M) |
| (9.60%) |
| 2019 | $1.52B | +$45.12M | +3.06% |
| 2018 | $1.47B | +$284.20M | +23.92% |
| 2017 | $1.19B | +$196.16M | +19.77% |
| 2016 | $992.08M | +$109.34M | +12.39% |
